This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Biocept Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Antonino Morales

İcra Kurulu Başkanı

US$781.6k

Toplam tazminat

CEO maaş yüzdesi	46.8%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	5.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Antonino Morales'un ücretlendirmesi Biocept'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$782k	US$366k	-US$32m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$57k	n/a	-US$3m

Tazminat ve Piyasa: Antonino 'nin toplam tazminatı ($USD 781.63K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 474.54K ).

Tazminat ve Kazançlar: Antonino şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Antonino Morales (67 yo)

less than a year

Görev süresi

US$781,631

Tazminat

Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Antonino Morales	CEO, President & Director	less than a year	US$781.63k	Veri yok
Darrell Taylor	Chief Legal Officer	1.5yrs	US$773.28k	0% € 0
Soon Hahn	Founder	26.6yrs	Veri yok	Veri yok
Rob Walsh	VP & Controller	less than a year	Veri yok	Veri yok
Philippe Marchand	Chief Operating Officer	1.4yrs	Veri yok	Veri yok
Pavel Tsinberg	Director of Technology Development	5.9yrs	Veri yok	Veri yok
David Moskowitz	Vice President of Strategy & Corporate Communications	6.8yrs	Veri yok	Veri yok
Veena Singh	Senior Medical Director	8.7yrs	US$441.87k	Veri yok

3.7yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: B00 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Antonino Morales	CEO, President & Director	2.1yrs	US$781.63k	Veri yok
Ivor Royston	Independent Director	13.6yrs	US$65.21k	0.00014% € 2.1
Linda Rubinstein	Independent Director	2.1yrs	US$57.26k	0% € 0
Quyen Dao-Haddock	Independent Director	less than a year	US$13.32k	0% € 0
Marsha Chandler	Independent Vice Chairman of the Board	9.8yrs	US$70.21k	0.000070% € 1.0
Fred Hirsch	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Bruce Gerhardt	Independent Chairman of the Board	12.8yrs	US$67.71k	0.0010% € 15.1

5.9yrs

Ortalama Görev Süresi

72yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: B00 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).

This company is no longer active

Biocept Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biocept, Inc. Announces Executive Changes

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

Full year 2022 earnings released: US$1.89 loss per share (vs US$0.19 loss in FY 2021)

No longer forecast to breakeven

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Investor sentiment improved over the past week

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: €6.05

New 90-day high: €5.10

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

New 90-day high: €4.80

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Biocept, Inc. Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, Including Cancer Cells

Biocept, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Biocept, Inc. Provides Update on COVID-19 Testing with More than 50,000 Specimens Received

New 90-day low: €3.62

Biocept, Inc. Announces That Highmark Has Made A Positive Coverage Determination on Target Selector Liquid Biopsy

New 90-day low: €3.69

Biocept, Inc. Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More Than 20,000 Specimens Processed

New 90-day low: €3.69

New 90-day low - €3.69

New 90-day low - €0.37

Biocept, Inc. Announces One-For-Ten Reverse Stock Split to Regain Compliance

First half earnings released

New 90-day high - €0.92

Biocept, Inc. to Report Q2, 2020 Results on Aug 12, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş